Eliason J F, Ramuz H, Yoshikubo T, Ishikawa T, Yamamoto T, Tsuruo T
Department of Oncology, Nippon Roche Research Center, Kamakura, Japan.
Biochem Pharmacol. 1995 Jul 17;50(2):187-96. doi: 10.1016/0006-2952(95)00115-g.
Dithiane analogues of tiapamil are highly active as modifiers of P-glycoprotein mediated multidrug resistance (MDR) in vitro. In an assay using the P-glycoprotein over-expressing cell line KB-8-5, the most active analogues for decreasing vincristine resistance were the racemate Ro 11-5160 and its two enantiomers, Ro 44-5911 (R) and Ro 44-5912 (S). In the KB-8-5 assay, the resistance modification index (RMI) of Ro 11-5160 was approximately 12-fold higher than those of the most active reference compounds tested, dipyridamole, cepharanthine, reserpine and cyclosporin A, when compared at concentrations equal to one-tenth of the IC50 of each compound (RMI0.1). The enantiomers have similar resistance modifying activities, but the (S) enantiomer Ro 44-5912 is somewhat more active, fully reverting the vincristine sensitivity of KB-8-5 cells to the level of the parental KB-3-1 cells at a concentration of 2 microM. The (R) enantiomer attained this level of modification at a concentration of 3.5 microM. These concentrations are both well below their IC50 values for KB-8-5 cells (150 microM). The enantiomers appear to interact with P-glycoprotein because they inhibited [3H]azidopine and [3H]-vinblastine binding to plasma membrane fractions prepared from resistant K562/ADR cells. However, in addition to their resistance modifying activities with KB-8-5 cells, these compounds also decreased the IC50 values of vincristine and doxorubicin with KB-3-1 cells that do not express detectable levels of P-glycoprotein. Ro 44-5911 overcame doxorubicin and vincristine resistance in three colorectal cancer cell lines (DLD-1, WiDr and COLO 201) that express P-glycoprotein. No effect was seen with the 3 colorectal cell lines on the IC50 values of three drugs not related to the MDR phenotype, 5-fluorouracil, 5'-deoxy-5-fluorouridine and cis-diaminodichloroplatinum (II). The in vitro vasodilatory activity of these dithianes, measured with strips of rat aorta contracted with KCl, was about 5% of that of verapamil. These results suggest that diathianes could be useful agents for MDR modification in vivo.
噻帕米的二噻烷类似物在体外作为P-糖蛋白介导的多药耐药性(MDR)修饰剂具有高度活性。在使用过表达P-糖蛋白的细胞系KB-8-5的试验中,降低长春新碱耐药性最具活性的类似物是外消旋体Ro 11-5160及其两种对映体Ro 44-5911(R)和Ro 44-5912(S)。在KB-8-5试验中,当以每种化合物IC50的十分之一浓度(RMI0.1)进行比较时,Ro 11-5160的耐药性修饰指数(RMI)比所测试的活性最高的参考化合物双嘧达莫、千金藤素、利血平和环孢素A高约12倍。对映体具有相似的耐药性修饰活性,但(S)对映体Ro 44-5912活性稍高,在2 microM浓度下可使KB-8-5细胞对长春新碱的敏感性完全恢复到亲本KB-3-1细胞的水平。(R)对映体在3.5 microM浓度下达到这种修饰水平。这些浓度均远低于它们对KB-8-5细胞的IC50值(150 microM)。对映体似乎与P-糖蛋白相互作用,因为它们抑制了[3H]叠氮平以及[3H]长春碱与从耐药K562/ADR细胞制备的质膜组分的结合。然而,除了对KB-8-5细胞的耐药性修饰活性外,这些化合物还降低了长春新碱和阿霉素对不表达可检测水平P-糖蛋白的KB-3-1细胞的IC50值。Ro 44-5911克服了三种表达P-糖蛋白的结肠癌细胞系(DLD-1、WiDr和COLO 201)对阿霉素和长春新碱的耐药性。这三种结肠癌细胞系对与MDR表型无关的三种药物5-氟尿嘧啶、5'-脱氧-5-氟尿苷和顺二氯二氨铂(II)的IC50值没有影响。用氯化钾收缩的大鼠主动脉条测定,这些二噻烷的体外血管舒张活性约为维拉帕米的5%。这些结果表明二噻烷可能是体内MDR修饰的有用药物。